智通财经APP获悉，和铂医药-B(02142)涨超5%，截至发稿，涨5.46%，报13.94港元，成交额1719.69万港元。
消息面上，据和铂医药官微消息，近日，公司与Evinova在第八届中国国际进口博览会(进博会)上宣布达成战略合作。根据合作协议，和铂医药与Evinova中国将共同应用AI与数字化技术，提升创新生物疗法的开发效率。双方将依托各自优势，构建AI驱动药物研发的开放式生态系统。
此前，在上海举办全球研发日活动上，和铂医药正式发布其Hu-mAtrIx™人工智能平台驱动的首个全人源AIHCAb模型——全人源重链抗体(HCAb)生成和筛选模型。该模型基于和铂医药专有的HarbourMice®平台数据，集成了一个微调的大型语言模型(LLM)用于序列生成，并辅以高精度的AI分类和成药性预测模型。与传统筛选方法不同，该平台实现了AI设计、智能筛选与湿实验验证的闭环流程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.